Gene Therapy Based on Gemcitabine Chemosensitization Suppresses Pancreatic Tumor Growth

Molecular Therapy

Volumn 14, Issue 6, 2006, Pages 758-767

  Vernejoul, Fabienne ^a   Ghénassia, Laurent ^b   Souque, Anny ^a   Lulka, Hubert ^a   Drocourt, Daniel ^b   Cordelier, Pierre ^a   Pradayrol, Lucien ^a   Pyronnet, Stéphane ^a   Buscail, Louis ^a   Tiraby, Gérard ^b  

^a CHU RANGUEIL   (France)

^b Zone industrielle de Montaudran   (France)

Author keywords

bystander effect; chemosensitization; deoxycytidine kinase; gemcitabine; in vivo gene therapy; pancreatic carcinoma; PEI

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE KINASE; DRUG METABOLITE; GEMCITABINE; POLYETHYLENEIMINE; UNCLASSIFIED DRUG; URIDINE PHOSPHATE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL NEOPLASM; FUSION GENE; GENE EXPRESSION; HAMSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; ORTHOTOPIC TRANSPLANTATION; PANCREAS CANCER;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CRICETINAE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; GENE THERAPY; GENETIC VECTORS; MALE; MESOCRICETUS; NEOPLASMS, EXPERIMENTAL; NUCLEOSIDE-PHOSPHATE KINASE; PANCREATIC NEOPLASMS;

CRICETINAE;

EID: 33751020539     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.07.010     Document Type: Article

References (34)

1. Warshaw A.L., and Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326 (1992) 455-465
2. Buscail L., Pages P., Berthelemy P., Fourtanier G., Frexinos J., and Escourrou J. Role of EUS in the management of pancreatic and ampullary carcinoma: a prospective study assessing resectability and prognosis. Gastrointest. Endosc. 50 (1999) 34-40
3. Burris III H.A. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 (1997) 2403-2413
4. Storniolo A.M., et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 (1999) 1261-1268
5. Lohr M., et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357 (2001) 1591-1592
6. Kasuya H., Nishiyama Y., Nomoto S., Hosono J., Takeda S., and Nakao A. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J. Surg. Oncol. 72 (1999) 136-141
7. Carrio M., Mazo A., Lopez-Iglesias C., Estivill X., and Fillat C. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. Int. J. Cancer 94 (2001) 81-88
8. Makinen K., Loimas S., Wahlfors J., Alhava E., and Janne J. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J. Gene Med. 2 (2000) 361-367
9. Evoy D., et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J. Surg. Res. 69 (1997) 226-231
10. Kanai F., et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. 58 (1998) 1946-1951
11. Rauchwerger D.R., Firby P.S., Hedley D.W., and Moore M.J. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 60 (2000) 6075-6079
12. Hapke D.M., Stegmann A.P., and Mitchell B.S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56 (1996) 2343-2347
13. Blackstock A.W., et al. Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin. Cancer Res. 7 (2001) 3263-3268
14. Kroep J.R., et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1 (2002) 371-376
15. Van Rompay A.R., Johansson M., and Karlsson A. Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme. Mol. Pharmacol. 56 (1999) 562-569
16. Liou J.Y., Dutschman G.E., Lam W., Jiang Z., and Cheng Y.C. Characterization of human UMP/CMP kinase and its phosphorylation of d- and l-form deoxycytidine analogue monophosphates. Cancer Res. 62 (2002) 1624-1631
17. Eliopoulos N., Cournoyer D., and Momparler R.L. Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother. Pharmacol. 42 (1998) 373-378
18. Beausejour C.M., Gagnon J., Primeau M., and Momparler R.L. Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem. Biophys. Res. Commun. 293 (2002) 1478-1484
19. Sandler A., and Ettinger D.S. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4 (1999) 241-251
20. D'Agostino G., Amant F., Berteloot P., Scambia G., and Vergote I. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 88 (2003) 266-269
21. Ruiz van Haperen V.W., et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54 (1994) 4138-4143
22. Mackey J.R., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58 (1998) 4349-4357
23. Goan Y.G., Zhou B., Hu E., Mi S., and Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 59 (1999) 4204-4207
24. Vernejoul F., et al. Antitumor effect of in vivo somatostatin receptor sst2 gene transfer in primary and metastatic cancer models. Cancer Res. 62 (2002) 6124-6131
25. Benali N., et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc. Natl. Acad. Sci. USA 97 (2000) 9180-9185
26. Carrere N., et al. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum. Gene Ther. 16 (2005) 1175-1193
27. Braakhuis B.J., Ruiz van Haperen V.W., Welters M.J., and Peters G.J. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur. J. Cancer 31A (1995) 2335-2340
28. Huang P., Chubb S., Hertel L.W., Grindey G.B., and Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51 (1991) 6110-6117
29. Manome Y., et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med. 2 (1996) 567-573
30. Bergman A.M., Pinedo H.M., and Peters G.J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist. Update 5 (2002) 19-33
31. Pearson A.S., et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin. Cancer Res. 5 (1999) 4208-4213
32. McClane S.J., Chirmule N., Burke C.V., and Raper S.E. Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration. Hum. Gene Ther. 8 (1997) 2207-2216
33. Goula D., Benoist C., Mantero S., Merlo G., Levi G., and Demeneix B.A. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 5 (1998) 1291-1295
34. Aoki K., et al. Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther. 8 (2001) 508-514